Humedix Co., Ltd. (KOSDAQ:200670)

South Korea · Delayed Price · Currency is KRW

25,650

-300 (-1.16%)

Oct 8, 2026, 3:30 PM KST

Market Cap	264.71B -49.9%
Revenue (ttm)	110.99B +12.7%
Net Income	9.06B -39.9%
EPS	963.99 -39.3%
Shares Out	10.32M
PE Ratio	26.61
Forward PE	6.45
Dividend	660.00 (2.57%)
Ex-Dividend Date	Aug 28, 2026

Volume	30,119
Open	26,000
Previous Close	25,950
Day's Range	25,100 - 26,050
52-Week Range	21,050 - 52,700
Beta	0.37
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About Humedix

Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. Humedix Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 248

Stock Exchange KOSDAQ

Ticker Symbol 200670

Full Company Profile

Financial Performance

In 2021, Humedix's revenue was 110.99 billion, an increase of 12.70% compared to the previous year's 98.48 billion. Earnings were 9.06 billion, a decrease of -39.91%.

Financial Statements